Session » RA – Diagnosis, Manifestations, and Outcomes Poster IV

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1973

Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1965

Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis

1:00PM-3:00PM: Abstract Number: 1952

Burden of Disease in Refractory Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1972

Comprehensive Investigation of Pain and Inflammation in Rheumatoid Arthritis from a Multidisciplinary Approach

1:00PM-3:00PM: Abstract Number: 1961

COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age

1:00PM-3:00PM: Abstract Number: 1971

Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment

1:00PM-3:00PM: Abstract Number: 1957

Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis

1:00PM-3:00PM: Abstract Number: 1970

Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies

1:00PM-3:00PM: Abstract Number: 1954

Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews

1:00PM-3:00PM: Abstract Number: 1968

Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1966

Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1956

Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study

1:00PM-3:00PM: Abstract Number: 1975

Identifying MicroRNAs Associated with Neuropathic Pain in Patients with Rheumatoid Arthritis (RA)

1:00PM-3:00PM: Abstract Number: 1962

Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease

1:00PM-3:00PM: Abstract Number: 1960

Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year

1:00PM-3:00PM: Abstract Number: 1959

Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database

1:00PM-3:00PM: Abstract Number: 1951

Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1963

Lipid Screening and Statin Use in Rheumatoid Arthritis Patients in an Underserved Population

1:00PM-3:00PM: Abstract Number: 1950

Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1953

Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively

1:00PM-3:00PM: Abstract Number: 1976

Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019

1:00PM-3:00PM: Abstract Number: 1955

Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients

1:00PM-3:00PM: Abstract Number: 1967

Sex Differences in Employment Outcomes in Patients with Recent Onset Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1964

Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate

1:00PM-3:00PM: Abstract Number: 1979

Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients

1:00PM-3:00PM: Abstract Number: 1977

Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy

1:00PM-3:00PM: Abstract Number: 1958

The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry

1:00PM-3:00PM: Abstract Number: 1969

The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis

1:00PM-3:00PM: Abstract Number: 1978

Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1974

Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].